Why is Parmax Pharma falling/rising?

As of 22-Aug, Parmax Pharma Ltd is experiencing a price increase, with its current price at 36.79, reflecting a change of 0.59 or 1.63% upward. Despite this positive movement today, the stock has shown a negative performance over the past week and month, with declines of 4.54% and 5.67%, respectively. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 51.17% compared to the 5-day average. While the stock has outperformed its sector by 1.29% today, it faces challenges due to a negative book value and weak long-term fundamentals, including poor growth in net sales and operating profit over the past five years.
In the broader market context, the Sensex has shown a slight positive return of 0.88% over the past week, contrasting with Parmax Pharma's decline during the same period. Although the stock has generated an 8.17% return over the past year, it has underperformed significantly compared to the benchmark, which has returned 0.31%. The company's weak ability to service its debt and negative EBITDA further contribute to its risk profile, suggesting that while there may be short-term gains, the long-term outlook remains precarious. Overall, the stock's recent rise appears to be an anomaly in the face of ongoing fundamental weaknesses and broader market trends.